Clinical trials: Hepatitis, Viral, Human
Hepatitis C, Chronic
Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). This study will assess the safety, antiviral activity, and pharmacokinetics of GSK2336805 alone and in…
- Trial name
- NCT01439373
- Testing
- GSK2336805, Pegylated interferon alfa-2a, Ribavirin
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
NAFLD, Hepatocellular Carcinoma
Utilization of MAsS in Patients Undergoing LT for HCC
The aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma.
- Conditions
- NAFLD, Hepatocellular Carcinoma, Liver Diseases, Liver Cancer
- Trial name
- NCT05184283
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
Hepatocellular Carcinoma, Hepatocellular Cancer
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis
- Trial name
- NCT05064553
- Testing
- Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
- Where
- 76 sites in United States
- Volunteers
- 2,990 people
- Sponsor
- Exact Sciences Corporation
Hepatitis E
Seroprevalence of Hepatitis E in People With an Organ Transplant
Background: The hepatitis E virus causes an acute hepatitis that usually goes away by itself. Researchers in France studied people who received a liver or kidney transplant.
- Trial name
- NCT02190253
- Where
- 3 sites in United States
- Volunteers
- 447 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B, Chronic Hepatitis D
Lamivudine for Chronic Hepatitis B
Chronic hepatitis B is a disease of the liver caused by the hepatitis B virus. It affects nearly 1 million Americans. Approximately 25% of patients with chronic hepatitis B will develop liver cirrhosis and 5% of patients will…
- Conditions
- Chronic Hepatitis B, Chronic Hepatitis D, Glomerulonephritis, Polyarteritis Nodosa
- Trial name
- NCT00001457
- Testing
- Lamivudine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cirrhosis
Comparison of Standard Dose Versus Once a Day Intravenous Albumin in Spontaneous Bacterial Peritonitis
The standard recommended management of spontaneous bacterial peritonitis (SBP) includes a third-generation cephalosporin (cefotaxime or ceftriaxone) and high dose albumin (1.5g/kg on day 1 and 1g/kg on day 3).
- Trial name
- NCT02756741
- Testing
- ALBUMIN
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences
HIV (Human Immunodeficiency Virus), Hepatitis C
Testing of a Navigation Intervention for Hepatitis C and HIV
This study will evaluate the efficacy of navigation for hepatitis C treatment in people living with both HIV and HCV with criminal justice involvement.
- Trial name
- LINKHCV (NCT04499651)
- Testing
- Navigation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Human Immunodeficiency Virus, Chronic Hepatitis C
Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment
The purpose of this study is to investigate T-cell mediated immune responses to HIV-1 and HCV and determine how these responses are affected by HCV treatment and correlates to response.
- Trial name
- DICO (NCT00909129)
- Testing
- pegylated interferon-alpha (Pegasys), ribavirin (COPEGUS)
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Karolinska Institutet
Chronic Hepatitis B
Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B
The purpose of this study is to evaluate the safety and efficacy of Domestic Tenofovir Disoproxil Fumarate Tablets in Chinese patients with hepatitis B ,compared with Tenofovir Disoproxil Fumarate Tablets of Gilead.
- Trial name
- NCT02287857
- Testing
- Domestic Tenofovir Disoproxil Fumarate Tablets, Tenofovir Disoproxil Fumarate Tablets of Gilead
- Where
- 15 sites in China
- Volunteers
- 360 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis C, Chronic
A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of setrobuvir in patients with genotype 1 chronic hepatitis C.
- Trial name
- NCT01903954
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus], setrobuvir
- Volunteers
- 283 people
- Sponsor
- Hoffmann-La Roche
Advanced Hepatocellular Carcinoma
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced…
- Trial name
- NCT04000737
- Testing
- Sorafenib+YIV-906
- Where
- 24 sites in United States, China and 2 more
- Volunteers
- 62 people
- Sponsor
- Yiviva Inc.
Hepatitis C
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin (RBV) patients with chronic hepatitis C (HCV)…
- Trial name
- NCT01500772
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 60 sites in United States, Canada and 6 more
- Volunteers
- 6 people
- Sponsor
- Debiopharm International SA
Hepatitis B, Human Papilloma Virus
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Aim: The main goal of this quantitative epidemiological observational study is to determine the prevalence of Human Papilloma Virus (HPV) infection and Hepatitis B (Hep B) immunity amongst women of childbearing age.
- Conditions
- Hepatitis B, Human Papilloma Virus, Mental Health Issue, Cancer Liver
- Trial name
- NCT06786429
- Testing
- Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy
- Volunteers
- 2,140 people, healthy volunteers welcome
- Sponsor
- Eunice Dube
Hepatitis C, Chronic
Hepatitis C Surveillance With Linkage to Care of Patients From Non-ID Departments in Jiangsu
Due to the occult nature of hepatitis C virus (HCV), it is estimated that less than 5% of people with chronic hepatitis C (CHC) infection knowing their status.
- Trial name
- NCT03772002
- Testing
- HCV screening
- Where
- 2 sites in China
- Volunteers
- 600 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Hepatitis C
Effect of Direct-acting Antiviral Drugs on Erectile Function
Effect of direct-acting antiviral drugs on erectile function
- Trial name
- NCT03444272
- Testing
- Sofosbuvir and Daklatasuvir
- Where
- Egypt
- Volunteers
- 105 people
- Sponsor
- Sherief Abd-Elsalam
Hepatitis D
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
This is an open-label, randomized, multi-center study in patients with chronic HBV and HDV co-infection.
- Trial name
- NCT05467553
- Testing
- Ursodeoxycholic acid, Ropeginterferon alfa-2b, Tenofovir Alafenamide
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Hepatitis B
A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects
This study is a randomized, double-blind, placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects, and the trial is planned to enroll 60 healthy subjects.
- Trial name
- NCT06160895
- Testing
- TQ-A3334 tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis D, Hepatitis B
Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
In China, there is no recommendation for Hepatitis D virus (HDV) screening, but the fact is estimated that one-third of the world's population of individuals with chronic Hepatitis B virus (HBV) infection live in China while we…
- Conditions
- Hepatitis D, Hepatitis B, Antibodies; Anti-D, RNA Virus Infections
- Trial name
- NCT05394623
- Testing
- HDV-Ab (IgG), HDV-RNA, RNA genotype
- Volunteers
- 5,000 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatitis B, Chronic
Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy
The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467
- Trial name
- NCT02631096
- Testing
- ARB-001467
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 36 people
- Sponsor
- Arbutus Biopharma Corporation
Hepatitis B, Hepatitis B Infection
Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings
A prospective cross-sectional study in which surgically non-invasive sample-taking is done only for the purpose of testing the samples on iStatis HBsAg Test at the point of care.
- Trial name
- NCT06368479
- Testing
- iStatis HBsAg Test
- Where
- South Africa
- Volunteers
- 1,400 people
- Sponsor
- bioLytical Laboratories
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.